(Monday, 7/30/2018) 1:45 PM - 3:45 PM
Room: Davidson Ballroom B
This opening session of the Quantitative Imaging Specialty Track will provide an overview of the translation of quantitative imaging biomarker applications from academic centers of excellence to clinical research applications and, ultimately, to the practice of precision medicine. Undoubtedly, quantitative imaging biomarkers will be critical to the practice of precision medicine. Therefore, radiology and radiation oncology are uniquely poised to be enablers of the precision medicine initiative. The recent rapid growth in artificial intelligence applications and imaging genomics applications highlight the need for an evolution of the practice of radiology from a mostly qualitative subjective art to a more quantitative objective science. In addition, these applications benefit from quantitative imaging data that has been acquired in a standardized manner. This session will highlight applications where quantitative imaging biomarker applications are critical, including those in radiomics, imaging genomics, artificial intelligence, and other applications in radiology, radiation oncology, and medical oncology. Additionally, the session will highlight the initiatives of two organizations seeking to specifically address the translation of quantitative imaging biomarkers from dedicated research applications to clinical trial research and clinical practice: the RSNA Quantitative Imaging Biomarkers Alliance (QIBA) and the NCI Quantitative Imaging Network (QIN).
Learning Objectives:
1. Understand when and why quantitative imaging is important in clinical trial research and clinical practice.
2. Understand why quantitative imaging biomarkers are critical in radiomics, imaging genomics, and artificial intelligence applications.
3. Understand the importance of quantitative imaging biomarkers in medical oncology applications.
4. Understand the role of the NCI Quantitative Imaging Network (QIN) and the RSNA Quantitative Imaging Biomarkers Alliance (QIBA) in translating quantitative imaging biomarkers from academic research to clinical trial research and clinical applications.
Funding Support, Disclosures, and Conflict of Interest: Giger Funding: NIH U01CA195564, U01CA189240, and R01CA166945, CTSA UL1TR000430. Giger Disclosures: Stockholder R2/Hologic, Co-Founder/Equity Holder Quantitative Insights, Shareholder QView, royalties from Hologic, GE Medical Systems, MEDIAN Technologies, Riverain Medical, Mitsubishi, Toshiba. Andriole Disclosure: Director, Research Strategy & Operations at MGH & BWH with support from Nvidia, General Electric and Nuance
Handouts
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email
